CLINICAL RESEARCH: HEART RHYTHM DISORDER
Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy
Jeffrey J. Goldberger, MD, FACC*,*,
Haris Subacius, MA*,
Andi Schaechter, RN*,
Adam Howard, BA*,
Ronald Berger, MD, PhD, FACC ,
Alaa Shalaby, MD, FACC ,
Joseph Levine, MD ,
Alan H. Kadish, MD, FACC* for the DEFINITE Investigators
* Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, and the Division of Cardiology, Feinberg School of Medicine, Chicago, Illinois
Johns Hopkins Hospital, Baltimore, Maryland
VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
Heart Center, St. Francis Hospital, Roslyn, New York.
Manuscript received February 14, 2006;
revised manuscript received May 5, 2006,
accepted May 15, 2006.
* Reprint requests and correspondence: Dr. Jeffrey Goldberger, Northwestern University Feinberg School of Medicine, 251 East Huron, Feinberg Pavilion 8-542, Chicago, Illinois 60611. (Email: j-goldberger{at}northwestern.edu).
OBJECTIVES: We sought to evaluate whether statins were associated with a survival benefit and significant attenuation in life-threatening arrhythmias in patients with nonischemic dilated cardiomyopathy.
BACKGROUND: Statins are associated with a reduction in appropriate implantable cardioverter-defibrillator (ICD) therapy in patients with coronary artery disease and improved clinical status in nonischemic dilated cardiomyopathy.
METHODS: The effect of statin use on time to death or resuscitated cardiac arrest and time to arrhythmic sudden death was evaluated in 458 patients enrolled in the DEFINITE (DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation) study. The effect of statin use on time to first appropriate shock was analyzed only in the 229 patients who were randomized to ICD therapy.
RESULTS: The unadjusted hazard ratio (HR) for death among patients on versus those not on statin therapy was 0.22 (95% confidence interval [CI] 0.09 to 0.55; p = 0.001). When controlled for statin effects, ICD therapy was associated with improved survival (HR 0.61; 95% CI 0.38 to 0.99; p = 0.04). There was one arrhythmic sudden death in the 110 patients receiving statin therapy (0.9%) versus 18 of 348 patients not receiving statins (5.2%; p = 0.04). The unadjusted HR for arrhythmic sudden death among patients on versus those not on statin therapy was 0.16 (95% CI 0.022 to 1.21; p = 0.08). The HR for appropriate shocks among patients on versus those not on statin therapy was 0.78 (95% CI 0.34 to 1.82) after adjustment for baseline differences in the two groups.
CONCLUSIONS: Statin use in the DEFINITE study was associated with a 78% reduction in mortality. This reduction was caused, in part, by a reduction in arrhythmic sudden death. These findings should be confirmed in a prospective, randomized clinical trial.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | CHF = congestive heart failure | | DEFINITE = DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation | | HR = hazard ratio | | ICD = implantable cardioverter-defibrillator | | LVEF = left ventricular ejection fraction | | NYHA = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
K. Rahimi, W. Majoni, A. Merhi, and J. Emberson
Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials
Eur. Heart J.,
February 3, 2012;
(2012)
ehs005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Braunschweig, G. Boriani, A. Bauer, R. Hatala, C. Herrmann-Lingen, J. Kautzner, S. S. Pedersen, S. Pehrson, R. Ricci, and M. J. Schalij
Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management
Europace,
December 1, 2010;
12(12):
1673 - 1690.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Mishkin, S. J. Saxonhouse, G. W. Woo, T. A. Burkart, W. M. Miles, J. B. Conti, R. S. Schofield, S. F. Sears, and J. M. Aranda Jr
Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge: Time to Go Beyond the Initial Shock
J. Am. Coll. Cardiol.,
November 24, 2009;
54(22):
1993 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Almroth, N. Hoglund, K. Boman, A. Englund, S. Jensen, B. Kjellman, P. Tornvall, and M. Rosenqvist
Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study
Eur. Heart J.,
April 1, 2009;
30(7):
827 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann
Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
415 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. Kostapanos, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf
Do statins have an antiarrhythmic activity?
Cardiovasc Res,
July 1, 2007;
75(1):
10 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Coplan and M. Ramos
Is There a Statin Effect on Arrhythmia and Survival in Patients With Nonischemic Cardiomyopathy?
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1372 - 1372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Goldberger and A. H. Kadish
Reply
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1372 - 1372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
